Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.250 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600mg and tenofovir disproxil fumarate 300mg in combination or telbivudine 600mg or tenofovir disproxil furmarate 300mg monothe | Professor Chan Henry Lik-Yuen |
| 2009.459 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600 mg and tenofovir disoproxil fumarate 300 mg in combination or telbivudine 600 mg or tenofovir disoproxil fumarate 300 mg monotherapy given over 12 weeks on the kinetics of hepatitis B virus DNA in adults with HBeAg positive compensated CHB | Dr. Leung WY Nancy |
| 2009.458 | A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Adminstered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus | Dr. Chow Chun Chung Francis |
| 2007.090 | A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept with Usual DMARD Therapy in Subjects with Rheumatoid Arthritis | Prof. Li Edmund |
| 2006.461 | A Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab As First-Line Therapy in Subjects with Metastatic Colorectal Cancer | Prof. Ma BY Brigette |
| 2003.275 | A Randomized, Open-Label Phase 3 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer | Prof. Mok Tony |
| 2024.483 | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | Prof. MA Brigette Buig Yue |
| 2019.679 | A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2014.487 | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) | Prof. MOK Tony S. K. |
| 2013.483 | A randomized, open label, phase II study: stereotactic body radiotherapy (SBRT) vs conventional intensity-modulated radiotherapy (IMRT) for low or intermediate risk prostate cancer in Asia population | Dr. POON Ming Chun |
| 2018.036 | A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877)compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy |
Dr. POON Darren Ming Chun 潘明駿醫生 |
| 2012.133 | A Randomized, Open Label, Multi-National Study of Cabazitaxel At 25 mg/m_ Every 3 Weeks in Combination With Prednisone Compared To Mitoxantrone in Combination With Prednisone in Asian Patients with Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen | Dr HO Wing-Ming |
| 2008.324 | A Randomized, Open Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney | Prof Ng Chi Fai |
| 2004.304 | A Randomized, Open Label Trial of Telbivudine (LdT) versus Adefovir Dipivoxil in Adults with HBeAg-Positive, Compensated Chronic Hepatitis B | Prof. Chan Lik Yuen Henry |
| 2004.323 | A Randomized, Open Label Trial of Telbivudine (LdT) versus Adefovir Dipivoxil in Adults with HbeAg-Positive, Compensated Chronic Hepatitis B | Dr. Leung Wai Yee Nancy |
| 2012.305 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment. | Dr. WONG Raymond Siu Ming |
| 2005.248 | A Randomized, Open Label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS_) or Adefovir Dipivoxil (ADV) in Patients with Lamivudine Resistant HBeAg Positive Chronic Hepatitis B | Prof. Sung JY Joseph |
| 2014.425 | A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy - SONAR: Study Of Diabetic Nephropathy with Atrasentan | Dr. OZAKI Risa |
| 2003.313 | A Randomized, Multicentre, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients with Mild-to-Moderate Dementia of the Alzheimer | Prof. Mok C.T. Vincent |
| 2017.606 | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients |
Prof. LI Chi Kong 李志光 |
| 2009.486 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | Associate Professor Ma Brigette |
| 2017.320 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
Prof. YEO Winnie 楊明明 |
| 2016.534 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2024.271 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301) | Dr. LI Molly Siu Ching |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2008.248 | A Randomized, Multicenter Phase II Study to Explore Whether Biomarkers Correlate with Treatment Outcome in Chemo-Na・e Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer, Who Receive Treatment with Bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in Addition to Carboplatin-based Chemotherapy (Gemcitabine or Paclitaxel) | Professor Mok Tony |
| 2001.233 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow C.C. Francis |
| 2002.328 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow Chun Chung Francis |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2015.689 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
Prof. YEO Winnie 楊明明 |
| 2008.086 | A Randomized, International, Double-Blinded (With In-House Blinding), Controlled with GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16-to 26-Year-Old Women | Prof. CHEUNG Tak Hong |
| 2020.187 | A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration |
Dr. BRELÉN Mårten 柏倫 |
| 2009.389 | A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema | Dr Lee Yau Wing Vincent |
| 2017.327 | A randomized, double-masked, clinical trial comparing extended vs standard endonasal dacryocystorhinostomy (ExStEND) for primary acquired nasolacrimal duct obstruction |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2014.222 | A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Effectiveness of Atorvastatin in Patients with Chronic Subdural Haematoma | Prof. POON Wai Sang |
| 2005.110 | A Randomized, Double-blind, Two-arms Placebo-controlled, Parallel-group, Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdoninally Obese Patients | Prof. Brian Tomlinson |
| 2006.158 | A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300mg and 900mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients with A History of Renal Disease | Prof. Li Kwok Ming Edmund |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2003.398 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum | Prof. Ma Buig Yue Brigette |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2015.547 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2006.319 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ -333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study | Dr. Kwan Patrick |
| 2008.414 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects with Partial Onset Seizures, Followed by an Open-Label Extension Study | Prof. Kwan Patrick |
| 2010.200 | A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy | Prof. Tomlinson Brian |
| 2009.111 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared with Placebo in Subjects with Type 2 Diabetes Mellitus | Dr. Chow C.C. Francis |
| 2021.566 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease | Prof. SZETO Cheuk Chun |
| 2018.122 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneously Administered Tafoxiparin as an Adjuvant to Induction Therapy in Term Pregnant, Nulliparous Women with an unripe cervix |
Prof. LEUNG Tak Yeung 梁德楊教授 |
| 2012.481 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome | Prof. YAN Bryan Ping Yen |
Page 225 of 265.